58101-23-8Relevant articles and documents
Probing structural requirements for human topoisomerase I inhibition by a novel N1-Biphenyl fluoroquinolone
Delgado, Justine L.,Lentz, Sarah R.C.,Kulkarni, Chaitanya A.,Chheda, Pratik R.,Held, Hailey A.,Hiasa, Hiroshi,Kerns, Robert J.
, p. 109 - 130 (2019/04/10)
Fluoroquinolones substituted with N-1 biphenyl and napthyl groups were discovered to act as catalytically inhibitors of human topoisomerases I and II, and to possess anti-proliferative activity in vivo. Structural requirements for these novel quinolones t
Synthesis and antitumor activity of novel 4-(2-fluorophenoxy)quinoline derivatives bearing the 4-Oxo-1,4-dihydroquinoline-3-carboxamide moiety
Li, Sai,Jiang, Rui,Qin, Mingze,Liu, Haicheng,Zhang, Guangyan,Gong, Ping
, p. 521 - 533 (2013/07/26)
A series of 4-(2-fluorophenoxy)quinoline derivatives bearing the 4-oxo-1,4-dihydroquinoline-3-carboxamide moiety were designed, synthesized, and evaluated for their in vitro antitumor activity against the H460, HT-29, MKN-45, U87MG, and SMMC-7721 cancer cell lines. Most of the tested compounds showed potent activity and high selectivity toward the HT-29 and MKN-45 cell lines. Furthermore, compounds 21b, 21c, and 21i were further examined for their c-Met kinase activity and exhibited strong efficacy with IC50 values in the single-digit nanomolar range, which was comparable with the positive control foretinib. The most promising compound 21c showed excellent cytostatic activity with IC50 values from 0.01 to 0.53 μM against all tested cell lines, thus being 1.7-2.2 times more active than foretinib. Novel 4-(2-fluorophenoxy)quinoline derivatives bearing the 4-oxo-1,4-dihydroquinoline- 3-carboxamide moiety were evaluated for their in vitro antitumor activity against several cancer cell lines. Compounds 21b, 21c, and 21i were also examined for their c-Met kinase activity in comparison to foretinib. Compound 21c showed excellent cytostatic activity with IC50 values from 0.01 to 0.53 μM against all tested cell lines and higher activity than foretinib.
Quinolone- and naphthyridonecarboxylic acid derivatives
-
, (2008/06/13)
The invention relates to new quinolone- and naphthyridonecarboxylic acid derivatives which have hydrogen in the 6-position, to processes for their preparation, and to antibacterial compositions and feed additives containing them.